Triple-Drug cocktail shows promise in Hard-to-Treat cancers
NCT ID NCT04850755
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a combination of three drugs—selinexor, nivolumab, and ipilimumab—in 11 adults with advanced or metastatic solid tumors that had stopped responding to standard treatments. The main goal was to check the safety and tolerability of the combination, while also measuring how well it controlled tumor growth. Results help guide future research on this multi-drug approach.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCE SOLID MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National University Hospital, Singapore
Singapore, Singapore
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a new drug shrink Hard-to-Treat tumors?
- Can a Custom-Made immune cell vaccine turn the tide against solid tumors?